Compare Merck & Co., Inc. (MRK) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Prospect Capital Corporation — how do they compare? Merck & Co., Inc. trades at $142.16 (market cap $352.29B), while Prospect Capital Corporation trades at $1.83 (market cap $984.89M). The key difference: Merck & Co., Inc. is far larger — about 357.7× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (22.76%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Prospect Capital Corporation for 78 Days on average.
| MRK | PSEC | |
|---|---|---|
Market Cap | $352.29B | $984.89M |
Volume | 6,348,796 | 10,087,405 |
Sector | Health | Financials |
52-Week High | $156.43 | $3.05 |
52-Week Low | $82.49 | $1.82 |
Typical Hold Time | 98 Days | 78 Days |
Enterprise Value | $399.05B | $2.74B |
Dividend Yield | 2.38% | 22.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
PSEC trades at $1.82, down 0.55% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company has beaten EPS estimates for the last three quarters, though revenue and net income were negative in 2025. Recent news highlights dividend declarations and management commentary on market opportunities, but financial performance shows volatility with a sharp revenue decline in 2025.
The outlook is mixed; a low P/B ratio of 0.34 suggests potential undervaluation, but negative cash flow and inconsistent profitability pose risks. Analyst sentiment is cautious with a majority Hold rating. Key opportunities include dividend yield and earnings beats, while risks involve financial instability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
